Verastem presents duvelisib data at EHA 2018 annual meeting
Verastem announced one oral and three poster presentations at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden. Data were presented on the company's lead product candidate, duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-delta and PI3K-gamma. An oral presentation by Matthew Davids, Dana-Farber Cancer Institute, highlighted the latest data from a Phase Ib/II study evaluating duvelisib in combination with FCR as a frontline treatment in younger patients with chronic lymphocytic leukemia. Three poster presentations highlighted additional duvelisib data, including crossover extension results from the Phase 3 DUO study in patients with relapsed or refractory CLL/small lymphocytic lymphoma, and new biomarker analyses on the tumor microenvironment modulation from the DUOTM study and the Phase 2 DYNAMOTM study in patients with refractory indolent non-Hodgkin lymphoma, and the dual PI3K-delta and PI3K-gamma activity of duvelisib in the CONTEMPOTM study in patients with untreated follicular lymphoma who are treated with duvelisib in combination with CD20 antibody immunotherapy. Phase Ib/II study of duvelisib in combination with FCR [dFCR] achieved ORR of 94% and 76% bone marrow MRD negativity in frontline therapy in younger CLL patients. Duvelisib also demonstrated robust clinical activity in CLL with 73% ORR and a median of 15-month PFS in the DUO crossover study of patients who became relapsed/refractory to ofatumumab in DUO. Additional data support the hypothesis that duvelisib, a first-in-class dual inhibitor of PI3K delta/gamma, targets malignant B-cells directly and modulates the tumor microenvironment.